|  | 
| MechanismABCG2 inhibitors | 
|  | 
|  | 
|  | 
| Inactive Indication- | 
| Drug Highest PhasePhase 1 | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose and Food Effect Study of PORT-77 Administered Orally to Healthy Adult Participants
A First-in-Human 2-part, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose, and food effect, investigation of the administration of PORT-77 in healthy adult participants.
100 Clinical Results associated with Portal Therapeutics, Inc.
0  Patents (Medical) associated with Portal Therapeutics, Inc.
100 Deals associated with Portal Therapeutics, Inc.
100 Translational Medicine associated with Portal Therapeutics, Inc.